retatrutide joint pain (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Retatrutide Weight Loss Results:Trial Data

Ma Y, Lee E, Yoshikawa H, Noda T, Miyamoto J, Kimura I, et al

Safety and Side Effects of Retatrutide During its clinical trials, Retatrutide displayed a safety profile similar to other GLP-1 medications

And check our guide on the best fiber supplements for GLP-1 users if this is an ongoing issue

The list includes the development of methods to address nitrosamine impurities, improving the evaluation of complex drug-device combination products, and studying equivalence approaches for complex active ingredients

Proper storage requires refrigeration at 2-8 degrees Celsius

In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what is observed after a body weight loss